The technical review for clinical trials of implantable sacral nerve stimulation system needs to focus on the basic principles of trials, clinical institutition and design elements of clinical trial protocols.
ZHANG Yu-jing
,
LIAO Li-min
,
LI Wei
,
YAN Xiao-yan
,
LIU Xiao-yan
,
XU Wei
. Requirements of Technical Review for Clinical Trial for Implantable Sacral Nerve Stimulation System[J]. Chinese Journal of Rehabilitation Theory and Practice, 2019
, 25(4)
: 493
-496
.
DOI: 10.3969/j.issn.1006-9771.2019.04.023
[1] 袁媛,姜长青,陈玥,等. 神经调控技术的发展与展望[J]. 生命科学仪器, 2018, 16(纪念刊): 20-28.
[2] GoldmanH B, LloydJ C, NoblettK L, et al. International Continence Society Best Practice Statement for Use of Sacral Neuro-Modulation [J]. Neurourol Urodyn, 2018, 37(5): 1823-1848.
[3] OerlemansD J A J. Evolution of neuromodulation for lower urinary tract dysfunction: past, present and future [M/OL]. 2017. https://www.researchgate.net/publication/315796765
[4] 中华人民共和国国务院. 医疗器械监督管理条例[EB/OL]. (2017-05-04). http://samr.cfda.gov.cn/WS01/CL0784/237491.html.
[5] 国家食品药品监督管理总局. 医疗器械注册管理办法[EB/OL]. (2014-07-30). http://samr.cfda.gov.cn/WS01/CL0053/103756.html.
[6] 食品药品监管总局,国家卫生计生委. 医疗器械临床试验质量管理规范[EB/OL]. (2016-03-01). http://samr.cfda.gov.cn/WS01/CL0053/148101.html.
[7] 国家食品药品监督管理总局. 国家食品药品监督管理总局关于医疗器械临床试验备案有关事宜的公告[EB/OL]. (2015-07-03). http://samr.cfda.gov.cn/WS01/CL0087/123460.html.
[8] 食品药品监管总局,国家卫生计生委. 医疗器械临床试验机构条件和备案管理办法[EB/OL]. (2017-11-15). http://samr.cfda.gov.cn/WS01/CL0050/217368.html.
[9] 食品药品监督管理总局. 医疗器械临床试验设计指导原则[EB/OL]. (2018-01-04). http://samr.cfda.gov.cn/WS01/CL0087/221976.html.
[10] FDA. Guidance for industry and FDA staff－clinical investigations of devices indicated for the treatment of urinary incontinence [EB/OL]. (2011-03-08). https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm.
[11] 张家振,刘斌,翟豹,等. 人工髋关节假体临床试验设计探讨[J]. 中国医疗器械杂志, 2018, 42(4): 262-264.
[12] BlokB, van KerrebroeckP, de WachterS, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder [J]. Neurourol Urodyn, 2018, 37(S2): S9-S16.
[13] SiegelS, NoblettK, MangelJ, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder [J]. Neurourol Urodyn, 2015, 34(3): 224-230.
[14] NoblettK, SiegelS, MangelJ, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder [J]. Neurourol Urodyn, 2016, 35(2): 246-251.
[15] SiegelS, NoblettK, MangelJ, et al. Three-year follow-up results of a prospective,multicenter study in overactive bladder subjects treated with sacral neuromodulation [J]. Urology, 2016, 94: 57-63.
[16] NoblettK, BergK C, KanF, et al. Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients [J]. Neurourol Urodyn, 2018, 37(5): 1667-1671.
[17] AbramsP, AnderssonK E, BirderL, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence [J]. Neurourol Urodyn, 2010, 29(1): 213-240.
[18] 食品药品监督管理总局. 膀胱过度活动症药物临试验指导原则[EB/OL]. (2017-12-25). http://samr.cfda.gov.cn/WS01/CL0087/221406.html.
[19] 骶神经调控术临床应用专家共识编写组. 骶神经调控术临床应用中国专家共识再版[J]. 中华泌尿外科杂志, 2018, 39(11): 801-804.
[20] SiegelS, NoblettK, MangeJ, et al. Five-year followup results of a prospective, mulicenter study of patients with overactive bladder treated with sacral neuromodulation [J]. J Urol, 2018, 199(1): 229-236.
[21] FDA. Guidance for industry and FDA staff－balancing premarket and postmarket data collection for devices subject to premarket approval [EB/OL]. (2015-04-13). https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm393994.pdf.
[22] 食品药品监督管理总局. 药物临床试验的一般考虑指导原则[EB/OL]. (2017-01-18). http://samr.cfda.gov.cn/WS01/CL0087/168752.html.
[23] 食品药品监督管理总局. 药物临床试验的生物统计学指导原则[EB/OL]. (2016-06-01). http://samr.cfda.gov.cn/WS01/CL0087/154780.html.
[24] 食品药品监管总局. 持续葡萄糖监测系统注册技术审查指导原则[EB/OL]. (2018-03-16). http://samr.cfda.gov.cn/WS01/CL0087/226783.html.
[25] 食品药品监管总局. 接受医疗器械境外临床试验数据技术指导原则[EB/OL]. (2018-01-10). http://samr.cfda.gov.cn/WS01/CL0087/222385.html.
